710 Medtronic Parkway, NE
Medtronic, headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world.
Founders: Earl Bakken and Palmer Hermundlie
CEO: Omar Ishrak
CFO: Karen Parkhill
CSO (Scientific): Richard Kuntz
Please click here for Medtronic job opportunities.
Tweets by Medtronic
2111 articles with Medtronic
Medtronic Valiant(TM) Captivia(TM) Demonstrates Durability, Safety, and Efficacy at Five Years in Transection Patients
New RESCUE Trial Data Presented in Blunt Thoracic Aortic Injury
Medtronic Announces Positive Results from the Largest ENB Study to Aid in Lung Cancer Diagnosis, Staging, and Treatment Preparation in a Single Minimally Invasive Procedure
Company Is Committed to Leading Evidence Generation Across the Lung Cancer Care Continuum
Medtronic Announces U.S. Commercial Launch of Mazor X Stealth(TM) Edition for Robotic-Assisted Spine Surgery
First U.S. Patients Treated Using Mazor X Stealth(TM) Edition at Norton Healthcare and Reston Hospital Center
DiamondTemp Ablation System Represents Disruptive RF Innovation
Patient-Level Survival Analysis Demonstrates No Link Between Paclitaxel Dose and Mortality in Patients Treated with IN.PACT Admiral DCB
Data Presented Today at LINC Reiterate Commitment to Patient Safety and Data Transparency
Medtronic Enrolls First Patient in Clinical Study to Assess Pain Control and Oral Opioid Elimination with Targeted Drug Delivery
Study Will Further Advance Understanding of Effectiveness and Tolerability of the SynchroMed(TM) II Intrathecal Drug Delivery System in Patients Who Have Weaned off Oral Opioids
Medtronic enrolls first patient in clinical study to assess pain control and oral opioid elimination with targeted drug delivery
Medtronic plc (NYSE:MDT) today announced the first patient enrolled in the Embrace TDD (targeted drug delivery) clinical study that will evaluate the use of the SynchroMed™ II intrathecal drug delivery system (“Medtronic pain pump”) as an alternative to oral opioids for patients with chronic intractable non-malignant primary back pain with or without leg pain.
Medtronic Launches Mobile App That Communicates Directly with World's First Smartphone-Connected Pacemakers
MyCareLink Heart(TM) Mobile App Allows Pacemaker Patients to Easily Stay Connected with Their Clinics
Medtronic Foundation Recognizes 12 Bakken Invitation Honorees for Driving Positive Change in Healthcare
Program Celebrates the Legacy of Medtronic Co-Founder Earl Bakken and Other Outstanding Patient Advocates Around the World
New Prediction Feature for Hypoglycemia Now Available in Sugar.IQ(TM) Personal Diabetes Assistant App, Developed by Medtronic and IBM Watson Health
IQcast Feature Aims to Predict the Likelihood of a Low Glucose Event Up to Four Hours in Advance
Medtronic plc today announced it will participate in the 37th Annual J.P. Morgan Healthcare Conference in San Francisco.
Intuitive and Discreet Device Provides Sacral Neuromodulation Therapy for Overactive Bladder and Bowel Incontinence
Medtronic plc today announced it has been named one of America's Most JUST Companies in 2018, according to Forbes magazineand JUST Capital, a nonprofit that ranks publicly-traded corporations on the issues Americans care about most.
The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2019 third quarter cash dividend of $0.50 per ordinary share, representing a 9 percent increase over the prior year.
12/5/2018Prior to being acquired by Medtronic, the two companies were involved in what the DOJ called kickback schemes to encourage unauthorized use of a medical device.
Medtronic Announces Worldwide Voluntary Field Corrective Action; Company Issues Software Update for Puritan Bennett(TM) 980 (PB980) Ventilator Series
Medtronic is notifying customers worldwide of a voluntary field corrective action for its Puritan Bennett(TM) 980 (PB980) ventilator series. Medtronic initiated this field action on September 19, 2018.
Study Will Evaluate Simultaneous Use of Radiofrequency and Cryo Surgical Ablation Devices in Cardiac Surgery Patients with Atrial Fibrillation
Acquisition to Augment Diabetes Capabilities with Nutritional Database and Data Science
Revenue of $7.5 Billion Increased 6.1% Reported; Increased 7.5% Organic
Mazor Robotics Ltd. today announced that at a Special General Meeting of Shareholders held earlier today, Mazor Robotics shareholders approved the previously announced definitive merger agreement with wholly-owned subsidiaries of Medtronic plc (NYSE: MDT).